UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000002304
Receipt number R000002812
Scientific Title Optimal Programming to Improve Mechanical Indices, Symptoms and Exercise in Cardiac Resynchronization Therapy
Date of disclosure of the study information 2009/08/06
Last modified on 2012/02/02 11:10:34

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Optimal Programming to Improve Mechanical Indices, Symptoms and Exercise in Cardiac Resynchronization Therapy

Acronym

Optimal Programming to Improve Mechanical Indices, Symptoms and Exercise in Cardiac Resynchronization Therapy (OPTIMISE CRT)

Scientific Title

Optimal Programming to Improve Mechanical Indices, Symptoms and Exercise in Cardiac Resynchronization Therapy

Scientific Title:Acronym

Optimal Programming to Improve Mechanical Indices, Symptoms and Exercise in Cardiac Resynchronization Therapy (OPTIMISE CRT)

Region

Japan Asia(except Japan) North America
Australia Europe


Condition

Condition

Heart Failure

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The objective of this study is to demonstrate that frequent paced/sensed AV and V-V delay optimization using QuickOpt in patients with CRT-D device results in improved clinical response and structural remodeling over standard care (i.e. empiric programming or one-time optimization using any non-IEGM optimization methods).

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

A combination of symptomatic improvement (>=1 class reduction in specific activity scale (SAS) or >= 25% improvement in 6 minute walk test distance) and LV remodeling (>= 15% reduction LV end systolic volume or >= 5% improvement in LVEF)

Key secondary outcomes

1) Rate of late (12-month) response to CRT
2) Changes in B-type natriuretic peptide (BNP) in correlation to cardiac remodeling
3) Inter- / intra-ventricular dyssynchrony compared to usual optimization


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Active

Stratification

YES

Dynamic allocation

NO

Institution consideration

Institution is considered as a block.

Blocking

YES

Concealment

Numbered container method


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Device,equipment

Interventions/Control_1

The paced / sensed AV and V-V delays will be optimized using QuickOpt. Optimization will be performed at enrollment, 3 month, 6 month, 9 month, 12 month and at any unscheduled follow-up visits.

Interventions/Control_2

The paced / sensed AV and V-V delays could be programmed empirically or optimized using any non-IEGM based method as per sites standard of care. Patients can be optimized only once within the first 4 weeks post implant.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Patient met standard CRT-D device indications (LVEF<= 35%, QRS >= 120 ms, NYHA Class III or ambulatory Class IV HF symptoms with optimal recommended medical therapy and at risk for sudden cardiac death or met the Japanese criteria for implantation of ICD) and was successfully implanted with an SJM CRT-D device with V-V timing and a compatible lead system.
2) Patient is willing to provide written informed consent.
3) Patient has the ability to complete a 6-minute hall walk test.
4) Patient is geographically stable and willing to comply with the required follow-up schedule.
5) Adequate echocardiographic images to measure LV end systolic volume will be available.

Key exclusion criteria

1) Patient has an epicardial ventricular lead system.
2) Patient has the ability to walk >= 450 meters in 6 minutes.
3) Patient has limited intrinsic atrial activity (<= 40 bpm).
4) Patient has persistent or permanent AF.
5) Patient has a second or third degree heart block.
6) Patient's life expectancy is less than 1 year
7) Patient is less than 18 years old.
8) Patient is pregnant.
9) Patient is on IV inotropic agents.

Target sample size

450


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Morio Shoda

Organization

Tokyo Women's Medical University Hospital

Division name

Cardiology

Zip code


Address

8-1 Kawada-cho, Shinjuku-ku, Tokyo Japan

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name

Organization

St. Jude Medical Japan Co., Ltd

Division name

Clinical Affairs

Zip code


Address

Column Minami Aoyama, 3Flr., 7-1-5, Minami-Aoyama, Minato-ku, Tokyo Japan

TEL

03-5766-8215

Homepage URL


Email



Sponsor or person

Institute

St. Jude Medical

Institute

Department

Personal name



Funding Source

Organization

St. Jude Medical Japan Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

University of Calgary (Derek Exner, MD)

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

YES

Study ID_1

NCT00489177

Org. issuing International ID_1

ClinicalTrials.gov

Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

東京女子医科大学病院(東京都)、他


Other administrative information

Date of disclosure of the study information

2009 Year 08 Month 06 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2008 Year 10 Month 08 Day

Date of IRB


Anticipated trial start date

2009 Year 06 Month 01 Day

Last follow-up date

2011 Year 11 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2009 Year 08 Month 06 Day

Last modified on

2012 Year 02 Month 02 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002812


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name